Go Back

Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

11.7.2022

BOSTON, Mass., and SEATTLE, Wash. – November 7, 2022Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

“Patients are the central motivation for all of our work at Affini-T, and now is an exciting time to be in the KRAS drug development space – tackling hard-to-treat solid tumors for patients with high unmet needs,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “We have observed encouraging preclinical potency and selectivity data for our KRAS G12V TCR-T cell therapy candidates that support further clinical translation and development. We look forward to presenting our findings at the SITC Conference in Boston.”

Oral Presentation and Poster details are as follows:

  • Abstract #244 Oral presentation: Clinical Session 206 Nov 11th 12:10-1:10 pm ET (and poster presentation Nov 11th 11:55 am-1:25 pm and 7:00-8:30 pm ET): AFNT-111, a preclinically safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation – Presenting Author: Hubert Lam, Ph.D., Vice President, Preclinical Development, Affini-T Therapeutics

 

  • Abstract #342 Poster presentation: Nov 11th 11:55 am-1:25 pm and 7:00-8:30 pm ET: KRAS G12V T cell receptor-engineered T cells expressing the durability FAS-41BB switch receptor exhibit a potent, persistent, coordinated CD4/CD8 anti-tumor response in vitro and in vivo – Presenting Author: Gary Shapiro, Ph.D., Vice President, Discovery Biology, Affini-T Therapeutics

 

About Affini-T Therapeutics

Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

Contacts

Media Contacts
Danielle Cantey
Evoke Canale
Danielle.Cantey@evokegroup.com
619-826-4657

Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388

Investor Contact
Ailsa Dalgliesh, PhD
ailsa@affinittx.com


Go Back